Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

May 14, 2018

Conditions
Metastatic Breast Cancer
Interventions
DRUG

MSI-1436C

Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Trial Locations (1)

11042

CFAM / Monter Cancer Center, Lake Success

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

DepYmed Inc.

INDUSTRY

lead

Northwell Health

OTHER